LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Novartis AG

Novartis AG

Cerrado

148.38 3.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

143.31

Máximo

148.46

Métricas clave
By Trading Economics
Ingresos	747M 3.2B
Ventas	189M 14B
P/B Media del Sector	20.871 49.888
BPA	1.65
Rentabilidad por dividendo	3.25
Margen de beneficios	23.336
Empleados	75,267
EBITDA	338M 5.4B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+13.62% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	3.25% 2.38%

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-351M 278B
Apertura anterior	144.84
Cierre anterior	148.38

Novartis AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2026, 09:05 UTC

Ganancias

Novartis Earnings Hit by Generic Competition -- Update

28 abr 2026, 05:51 UTC

Ganancias

Novartis Could Upgrade Future Growth Outlook

27 mar 2026, 10:24 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 mar 2026, 06:36 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 abr 2026, 09:18 UTC

Charlas de Mercado

Ganancias

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 abr 2026, 07:26 UTC

Charlas de Mercado

Ganancias

Novartis's Results Are Mixed -- Market Talk

28 abr 2026, 05:07 UTC

Ganancias

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 abr 2026, 05:05 UTC

Ganancias

Novartis: On Track to Deliver Full-Year Guiance

28 abr 2026, 05:04 UTC

Ganancias

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 abr 2026, 05:04 UTC

Ganancias

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 abr 2026, 05:03 UTC

Ganancias

Novartis 1Q Core EPS $1.99

28 abr 2026, 05:03 UTC

Ganancias

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 abr 2026, 05:02 UTC

Ganancias

Novartis 1Q Core Operating Profit $4.90B

28 abr 2026, 05:02 UTC

Ganancias

Analysts Saw Novartis 1Q Sales at $13.34B

28 abr 2026, 05:01 UTC

Ganancias

Novartis 1Q Sales $13.11B

28 abr 2026, 05:00 UTC

Ganancias

Novartis Backs 2026 View

28 abr 2026, 05:00 UTC

Ganancias

Novartis AG 1Q EPS $1.65

28 abr 2026, 05:00 UTC

Ganancias

Novartis AG 1Q Net Pft $3.2B

28 abr 2026, 05:00 UTC

Ganancias

Novartis AG 1Q Adj EPS $1.99

24 abr 2026, 05:20 UTC

Ganancias

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 abr 2026, 05:19 UTC

Ganancias

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 abr 2026, 05:19 UTC

Ganancias

Novartis: Prequalification Is a Process Run by the WHO

10 abr 2026, 11:45 UTC

Charlas de Mercado

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 abr 2026, 08:01 UTC

Charlas de Mercado

Novartis Likely to Confirm Guidance -- Market Talk

30 mar 2026, 09:37 UTC

Charlas de Mercado

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 mar 2026, 07:54 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 mar 2026, 06:22 UTC

Adquisiciones, fusiones, absorciones

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 mar 2026, 06:05 UTC

Adquisiciones, fusiones, absorciones

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 mar 2026, 06:04 UTC

Adquisiciones, fusiones, absorciones

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 mar 2026, 06:03 UTC

Adquisiciones, fusiones, absorciones

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Comparación entre iguales

Cambio de precio

Novartis AG previsión

Precio Objetivo

By TipRanks

13.62% repunte

Estimación a 12 Meses

Media 163.23 USD 13.62%

Máximo 180 USD

Mínimo 141 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novartis AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Novartis AG Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.